These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 10640759)

  • 1. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
    Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
    J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
    De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
    J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
    De Pascalis R; Gonzales NR; Padlan EA; Schuck P; Batra SK; Schlom J; Kashmiri SV
    Clin Cancer Res; 2003 Nov; 9(15):5521-31. PubMed ID: 14654532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
    Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
    Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
    Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
    Mol Immunol; 2003 Oct; 40(6):337-49. PubMed ID: 14522015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
    Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
    Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
    Kashmiri SV; Iwahashi M; Tamura M; Padlan EA; Milenic DE; Schlom J
    Crit Rev Oncol Hematol; 2001 Apr; 38(1):3-16. PubMed ID: 11255077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
    Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
    Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SDR grafting--a new approach to antibody humanization.
    Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
    Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
    Mateo C; Moreno E; Amour K; Lombardero J; Harris W; Pérez R
    Immunotechnology; 1997 Mar; 3(1):71-81. PubMed ID: 9154469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28.
    Tan P; Mitchell DA; Buss TN; Holmes MA; Anasetti C; Foote J
    J Immunol; 2002 Jul; 169(2):1119-25. PubMed ID: 12097421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of the immunogenicity of therapeutic antibodies.
    Gilliland LK; Walsh LA; Frewin MR; Wise MP; Tone M; Hale G; Kioussis D; Waldmann H
    J Immunol; 1999 Mar; 162(6):3663-71. PubMed ID: 10092828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
    Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
    Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
    Mersmann M; Schmidt A; Rippmann JF; Wüest T; Brocks B; Rettig WJ; Garin-Chesa P; Pfizenmaier K; Moosmayer D
    Int J Cancer; 2001 Apr; 92(2):240-8. PubMed ID: 11291052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments.
    Ichiyoshi Y; Casali P
    J Exp Med; 1994 Sep; 180(3):885-95. PubMed ID: 8064239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of antigen binding and idiotypic expression by antibodies with polyglycine-replaced complementarity-determining regions.
    Sompuram SR; Den W; Sharon J
    J Immunol; 1996 Feb; 156(3):1071-81. PubMed ID: 8557981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
    Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
    Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning of cDNAs encoding the variable domains of antibody KC4G3 and construction of a chimeric antibody.
    Couto JR; Blank EW; Peterson JA; Ceriani RL
    Hybridoma; 1993 Aug; 12(4):485-9. PubMed ID: 8244420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study.
    López-Requena A; Rodríguez M; de Acosta CM; Moreno E; Puchades Y; González M; Talavera A; Valle A; Hernández T; Vázquez AM; Pérez R
    Mol Immunol; 2007 Feb; 44(5):1015-28. PubMed ID: 16620986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody.
    Graves SS; Goshorn SC; Stone DM; Axworthy DB; Reno JM; Bottino B; Searle S; Henry A; Pedersen J; Rees AR; Libby RT
    Clin Cancer Res; 1999 Apr; 5(4):899-908. PubMed ID: 10213227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.